Four Swiss Health Valley biotech companies worth keeping an eye out for in 2024
Share this article
Labiotech.eu, a leading digital media covering the European Biotech industry, published a list of Swiss biotech companies to put on your radar.
Switzerland is home to a thriving biotech industry, with strong research institutions many companies leading the way in cutting-edge research for new cancer treatments and immunotherapies, from startups to multinationals. Labiotech highlighted a list of 18 Swiss biotech companies worth keeping an eye out for, including four from the Swiss Health Valley.
Haya Therapeutics
Located at Biopôle, Haya Therapeutics focuses on blocking long non-coding RNAs found in the human genome, which play a role in fibrotic diseases and other age-related health conditions, like cancer.
Their approach centres on the identification and modulation of lncRNAs, which are regulatory molecules derived from the “dark genome” — the non-coding regions of DNA. HAYA’s proprietary platform targets these lncRNAs with RNA-based therapeutics, such as modified antisense oligonucleotides (ASOs), to prevent and reverse pathological conditions like fibrosis.
iOnctura
iOnctura is a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers with precision oral small molecules that target cancers in novel ways. The bold new treatments extend lives and improve health spans, changing the outlook for patients and their families.
Newbiologix
NewBiologix develops cell lines and bioinformatics platforms to enhance the production of viral vectors. rAAV vectors are the preferred vehicles for delivering gene therapies due to their safety and effectiveness. They focus on optimising the production of these vectors using engineered cell lines.
Stalica
Stalica is fast-forwarding neuro precision treatments by deploying its neurodevelopmental precision medicine platform and addressing wider psychiatric and neurological disorders with a phase 3 drug candidate.
With state-of-the-art technology and clinical trials for Autism Spectrum Disorder (ASD) and Substance Use Disorder (SUD), STALICLA is changing the landscape of brain disease treatment.
Source: Labiotech.eu